Dripps, Isaac J.
Wang, Qin
Neubig, Richard R.
Rice, Kenner C.
Traynor, John R.
Jutkiewicz, Emily M.
Funding for this research was provided by:
Pharmaceutical Research and Manufacturers of America Foundation
National Institutes of Health (DA 035316)
Article History
Received: 22 June 2016
Accepted: 4 September 2016
First Online: 13 September 2016
Compliance with ethical standards
: All animal use procedures complied with the Guide for the Care and Use of Laboratory Animals by the National Institutes of Health and were approved by the University of Michigan Institutional Committee on the Use and Care of Animals.
: Part of this work was funded by a PhRMA Foundation Research Starter Grant awarded to EMJ and funds from the University of Michigan Medical School. She has consulted for Trevena, Inc., in 2011–2012 with compensation. JRT has no conflicts and is supported by the National Institute on Drug Abuse grant DA 035316. This study was also supported in part by the Intramural Research Program of the National Institute of Alcohol Abuse and Alcoholism and by the National Institute on Drug Abuse (KCR). RRN is founder and owner of Argessin LLC which holds a license for small-molecule RGS inhibitors and is supported by NIH DA RO1 023252.